Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference

Liquidia Executives to Present Business Update at Wells Fargo Annual Healthcare Conference

Liquidia Corporation announced that its COO/CFO and Chief Business Officer will provide a business update during a fireside chat at the Wells Fargo 21st Annual Healthcare Conference. The presentation will include insights on their proprietary PRINT technology, current marketed products, and investigational therapies for respiratory and vascular diseases. The webcast will be accessible on Liquidia’s investor webpage with a replay available for 30 days.

Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference

LQDA

Summarize with

ChatGPT Perplexity Claude Grok Gemini

Key Points

Liquidia's leadership to discuss business progress and strategy at a major healthcare investor conference.
The company is focused on respiratory and vascular disease treatments, including their PRINT technology and marketed drug YUTREPIA for pulmonary arterial hypertension (PAH).
Development of L606, an extended-release treprostinil formulation with a next-generation nebulizer, is underway, signaling pipeline growth.

MORRISVILLE, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Michael Kaseta, Chief Operating Officer and Chief Financial Officer, and Jason Adair, Chief Business Officer, will provide an update on the company’s business in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston on Tuesday, September 8, 2026 at 8:45 a.m. ET.

Access to this event will be available on the “Investors” page of Liquidia’s website at https://liquidia.com/investors/events-and-presentations. A replay of the webcast will be archived on the Company's website for at least 30 days.

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT® technology. PRINT enabled the development of YUTREPIA® (treprostinil) inhalation powder for the treatment of PAH and PH-ILD. The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.

Contact Information

Investors:
Jason Adair
Chief Business Officer
919.328.4350
[email protected]

Media:
[email protected]

Risks

Market acceptance and regulatory approval risks for investigational therapies like L606 could impact future growth.
Competition in the biopharmaceutical sector, especially for treatments of PAH and pulmonary diseases, might affect market share.
Reliance on successful commercialization of PRINT technology and maintaining intellectual property protections introduces operational uncertainties.

Menu

Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference

Key Points

Risks

More from Press Releases